If we are to minimize the now well-documented burdens of COVID-19 on cancer patients, governments must support innovations that improve their outcomes and cut through the healthcare roadblocks posed by the pandemic.

Canexia Health's Chief Scientific Officer writes about the importance of combining different approaches to obtain correct results for ctDNA diagnostics. While high sensitivity is important, it must be contextualized with other key measurements.

Here are three examples of value-based care initiatives that are also focused on reducing disparities and inequity in cancer care.

This article from The Globe and Mail covers Project ACTT, a federally funded project, led by Canexia Health, which offers the potential for a more efficient alternative for cancer testing that can save hospital resources and lower the risk of infection.

Dozens of major cancer centers and organizations across the US issued an urgent call to action: cancer screening and treatment during COVID-19 must resume at full speed and at full scale.

This technical note describes the NGS assays developed by Canexia Health for somatic testing of adult solid tumors and how they are made available through local laboratories via our proprietary technology transfer model.

Through Project ACTT, we are leading a consortium of partners to speed up cancer testing in Canada for targeted treatment selection during the pandemic through minimally invasive circulating tumor (ctDNA) testing. Here are some highlights from the project thus far.